Axsome Therapeutics Inc is trading 8.5% up at $275.00 in pre-market, extending a strong multi-day uptrend. - The company announced new data presentations on AXS-12 and solriamfetol at the SLEEP 2026 conference, which is taking place from June 14-17, 2026. - A presentation on "Symptom Burden and Quality of Life in Patients with Narcolepsy Who Experience Residual Cataplexy" was specifically scheduled for Tuesday, June 16, 2026. - This new data and ongoing conference presentations likely serve as a catalyst for the positive stock movement.